Quick Facts: Main Uses

• Addresses symptoms of Benign Prostatic Hyperplasia (BPH) in men.
• Helps manage issues like urinary frequency and urgency.
• Aids in improving weak urine stream and bladder emptying.

---

Alfuzosina Teva is authorized for the symptomatic management of Benign Prostatic Hyperplasia (BPH), also known as an enlarged prostate, in adult men. This medication helps address the lower urinary tract symptoms (LUTS) that are commonly associated with this condition.

The primary therapeutic benefit is to help ease the process of urination, which may be impacted by BPH. Individuals may experience an improvement in symptoms such as a frequent or urgent need to urinate, difficulty initiating the flow of urine, or a feeling of incomplete bladder emptying. By assisting with these issues, the treatment aims to maintain comfort and support quality of life related to urinary function. This medication helps manage BPH symptoms but is not a definitive cure and does not cause the prostate to shrink. Prior to initiating treatment, a healthcare provider should rule out the presence of prostate carcinoma, as both conditions may present similar symptoms. This treatment is not indicated for the management of hypertension.

Alfuzosina Teva is authorized for use only in adult men aged 18 and older. The medicine is not indicated for use in the pediatric population, and its eligibility status for women, including during pregnancy or lactation, is not applicable as it is prescribed for conditions exclusive to men.

Regulatory documents define several conditions under which the medicine is contraindicated (must not be used) or requires special caution.

Contraindicated Populations

• Patients with moderate or severe hepatic impairment (Child-Pugh categories B and C).
• Patients taking other alpha-1 receptor blockers or potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, or ritonavir).
• Patients with a known hypersensitivity to alfuzosin or other quinazoline derivatives.
• Patients with a history of orthostatic hypotension (as specified in some official labels).

Eligibility Restrictions

• Severe renal impairment (creatinine clearance <30 mL/min) requires caution or, according to some regulatory bodies, the medicine should not be administered.
• Caution is necessary for patients with certain pre-existing conditions, including coronary artery disease and conditions that may lead to QTc prolongation.
• Before treatment begins, prostate carcinoma must be ruled out by a healthcare provider, as this condition can mimic the approved indication.

Alfuzosina Teva Interactions with other medicines and products

Classification	Interacting Agents / Conditions
Formally Contraindicated	Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir); Other Alpha-Adrenergic Antagonists; Moderate/Severe Hepatic Impairment (Childs-Pugh B & C)
Use with Caution	Antihypertensive Medication (e.g., beta-blockers, Nitrates); Phosphodiesterase-5 (PDE5) Inhibitors; Medications that prolong the QT interval; Severe Renal Impairment (CrCl < 30 mL/min)

---

The drug's interaction profile is defined by its metabolic pathway and pharmacological class, as outlined in official regulatory documentation.

Metabolic & Exposure Interactions

Alfuzosin is primarily metabolized by the CYP3A4 enzyme. Co-administration with potent CYP3A4 inhibitors (like Ketoconazole) is contraindicated because this leads to a significant reduction in drug clearance and a three-fold or greater increase in alfuzosin exposure (AUC), which increases the potential for serious adverse events. Moderate inhibitors, such as Diltiazem, are documented to also increase alfuzosin plasma concentrations, requiring caution.

Pharmacodynamic Interactions

Alfuzosin should not be used in combination with other alpha-adrenergic antagonists due to expected additive hypotensive effects. Caution is also necessary when alfuzosin is used with antihypertensive medication (including beta-blockers and Nitrates) or PDE5 inhibitors (e.g., Sildenafil), as this combination of vasodilators can potentially cause symptomatic hypotension or syncope.

Population-Specific Constraints

Use is contraindicated in patients with moderate or severe hepatic impairment because reduced clearance results in a three- to four-fold higher plasma concentration compared to healthy subjects. Caution is advised for patients with severe renal impairment.

The following content adheres strictly to the constraints for a pure mechanism-of-action section, avoiding all therapeutic, symptomatic, dosing, or safety language.

Molecular Target: Competitive Blockade of Alpha-1 Receptors

Alfuzosina Teva operates via the competitive antagonism of post-synaptic alpha-1 adrenoceptors (alpha1-ARs) which are concentrated on the smooth muscle surrounding the prostate and bladder neck. This interaction effectively blocks the binding of the sympathetic neurotransmitter norepinephrine, suppressing the signaling cascade that typically mediates muscle contraction and tone.

Mechanistic Cascade: Modification of Smooth Muscle Tone

By inhibiting this signaling pathway, alfuzosin suppresses the release of intracellular calcium within the smooth muscle cells. This crucial molecular step leads directly to the relaxation of the muscular walls in the prostate and bladder neck, resulting in a reduction of urethral resistance and pressure at the bladder outlet, leading to a change in fluid passage dynamics.

Systemic Consequence: Functional Selectivity and Vasodilation

While the mechanism is functionally targeted toward the lower urinary tract, its alpha1-AR blockade also extends to the vascular smooth muscle in the rest of the body. This off-target mechanism of action causes vasodilation (widening of blood vessels), which results in a modification of systemic blood pressure.

Alfuzosina Teva is a 10 mg prolonged-release tablet intended strictly for oral administration. The standardized adult dosing regimen is one 10 mg tablet taken once daily, which also constitutes the maximum recommended daily dose. To ensure consistent drug absorption and predictable pharmacological action, the medicine must be taken with food and immediately following the same meal each day.

The administration method is highly specific to the tablet's design. The prolonged-release tablet must be swallowed whole with an adequate amount of fluid and must not be chewed, crushed, split, or divided under any circumstances. This constraint is mandatory to preserve the extended-release mechanism, which is designed to sustain drug delivery over a 24-hour period.

In terms of duration, the medicine is typically used as a long-term maintenance treatment for the symptomatic management of Benign Prostatic Hyperplasia (BPH). Clinical applications also define a short-term course of three to four days when it is used as adjunctive therapy for specific conditions like acute urinary retention.

The 10 mg prolonged-release tablet is not indicated for use in pediatric patients and is unsuitable for patients with severe impairment of liver or kidney function. Dose adjustment is generally not necessary for older adults (aged 65 years and above). If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular schedule resumed. It is strictly advised not to take a double dose to compensate for the missed amount.

Research evidence / Overview of Studies for Alfuzosina Teva

Evidence for Symptomatic Benign Prostatic Hyperplasia (BPH)

The foundational research for alfuzosin in the context of BPH explored the measurement of changes in the associated lower urinary tract symptoms (LUTS), such as frequent or urgent need to urinate and difficulty with urine flow. The primary evidence comes from Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive either alfuzosin or an inactive substance called a placebo. These trials contribute to research exploring how symptoms change over time. Outcomes related to physical discomfort and daily functioning were the main focus of these short-term studies.

Studies reported patterns observed in the studies regarding a change in symptom intensity, which was measured using standardized tools like the International Prostate Symptom Score (IPSS). Researchers also monitored changes in objective functional measures, primarily the Peak Urinary Flow Rate—a measure of how quickly a person can urinate—and the volume of Post-Void Residual (PVR) urine left in the bladder after emptying. In trials, alfuzosin was observed in adult men whose BPH symptoms were characterized by functional limitations.

---

Research on Post-Acute Urinary Retention (AUR) Management

Separate, specific RCTs were evaluated in a unique patient group: adult men who had recently experienced a first, spontaneous episode of Acute Urinary Retention (AUR) due to BPH. The research examined a key, short-term challenge: the ability to urinate successfully after the removal of a urinary catheter (known as a Trial Without Catheter, or TWOC).

Studies monitored the success rate of the TWOC procedure in this specific population. Findings indicate patterns related to TWOC success rates compared to a placebo. The long-term monitoring examined outcomes reflecting continued stability, such as the need for BPH-related surgery or recurrence.

---

What is Still Uncertain and Research Gaps

While the most controlled trials were short-term, long-term effects are not fully established, and follow-up studies extending up to a year, and sometimes longer, have been conducted. The evidence contributes to the broader evidence landscape by providing context on the sustained nature of the initial measured changes over extended periods. A key limitation is that the primary, highly controlled, placebo-controlled data applied in research contexts involving fluctuating or unstable symptoms are limited to relatively short time frames (typically 3 months). The results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly outside of those specific study conditions.

Common questions about Alfuzosina Teva (FAQ)

Q: Does Alfuzosina Teva shrink the size of the prostate gland?

A: Alfuzosina Teva is classified as an alpha-blocker, and official product information indicates it works by relaxing the smooth muscles in the prostate and bladder neck. It is not an agent that is indicated to change or shrink the physical size of the prostate gland itself.

Q: Is Alfuzosina Teva a medication for treating high blood pressure?

A: According to official product information, Alfuzosina Teva is not indicated as a primary treatment to lower high blood pressure. However, its mechanism of action (alpha-blockade) can cause vasodilation (widening of blood vessels), which may result in a known side effect of a decrease in systemic blood pressure.

Q: Is Alfuzosina Teva the same as other generic versions of Alfuzosin?

A: Regulatory agencies, such as the FDA, require that generic versions of a medicine are demonstrated to be bioequivalent to the original listed drug. This means the generic products should contain the same active ingredient and be therapeutically equivalent, achieving the same effect in the body as the reference product.

Q: How long does the feeling of dizziness or lightheadedness typically last after starting this medicine?

A: Regulatory documents indicate that effects such as dizziness and low blood pressure are often transient, meaning they occur at the beginning of treatment. These initial effects are typically temporary.

Q: What measures are recommended to reduce the risk of dizziness or fainting when taking Alfuzosina Teva?

A: Official health information describes that if symptoms of low blood pressure—such as dizziness or fainting—occur, resting in a lying position is appropriate. The guidance indicates resting should continue until the symptoms have completely disappeared.

Q: Can Alfuzosina Teva cause changes in sexual function or ejaculation?

A: Official safety documents report that certain changes in sexual function have been noted, though not commonly. These may include instances of impotence, a decreased interest in sexual activity, and ejaculatory disorders.

Q: What is 'priapism' and what is its relevance to Alfuzosina Teva?

A: Priapism is listed as a serious, but very rare, side effect associated with the use of Alfuzosina Teva. It is defined as a painful erection that persists for longer than four hours. Official guidance notes that this condition is a serious adverse event.

Q: Can Alfuzosina Teva cause symptoms similar to a common cold or a stuffy nose?

A: Yes, official safety data confirms that effects resembling a cold can occur. Rhinitis, which is inflammation of the nasal lining, and symptoms such as nasal congestion or a stuffy/runny nose are reported as uncommon side effects.

Q: How quickly should a person expect to see improvement in urinary symptoms after starting the medicine?

A: Clinical studies have measured an improvement in objective parameters, such as an increase in the peak urinary flow rate ( Q max), observed from the first dose compared to placebo. This indicates a relatively rapid onset of pharmacological action.

Q: What is the expected timeframe for Alfuzosina Teva to reach its full effect?

A: In clinical trials, researchers typically monitor the progressive changes in patient symptoms and flow rate over time. Significant and progressive change has been documented when comparing results at baseline to those seen at one month and three months.

Q: Are there any specific foods, like grapefruit, that should be avoided while taking Alfuzosina Teva?

A: Official information notes that grapefruit or grapefruit juice consumption is discouraged while using Alfuzosin. This restriction is due to the potential for grapefruit to significantly increase the concentration of the drug in the body, which raises the risk of low blood pressure.

Q: What types of over-the-counter medicines might interact with Alfuzosina Teva?

A: Official patient information describes the importance of checking all over-the-counter medicines, supplements, or herbal products with a healthcare professional. This is noted as a necessary step to identify potential interactions.

Q: Can people with pre-existing heart conditions take Alfuzosina Teva?

A: Official regulatory warnings advise caution when prescribing Alfuzosina Teva to patients with certain pre-existing heart conditions. Specifically, conditions like coronary artery disease and conditions that may lead to QTc prolongation (a change in the heart's electrical rhythm) are noted as needing careful consideration.

Q: Why is it important to tell an eye doctor about taking Alfuzosina Teva before cataract surgery?

A: Official regulatory warnings state that an eye surgeon must be informed of the current or past use of Alfuzosin. This is due to the risk of Intraoperative Floppy Iris Syndrome (IFIS), a specific complication that can occur during the surgery.

Q: What is the specific eye condition called Intraoperative Floppy Iris Syndrome (IFIS)?

A: IFIS is an eye condition observed in some patients who have taken alpha-blockers like Alfuzosin. Official safety information lists it as a potentially serious problem that can occur during cataract surgery.

Q: Is Alfuzosina Teva considered a uroselective alpha-blocker?

A: Alfuzosin is described in clinical data as a selective alpha-1 adrenoceptor antagonist. This means it has a functional uroselectivity and preferentially acts on the smooth muscle in the lower urinary tract, where it targets the symptoms of BPH.

Q: What are the general success rates mentioned in clinical research for Alfuzosina Teva?

A: Official reviews of clinical studies report that Alfuzosina Teva significantly increases the peak urinary flow rate ( Q max) and significantly reduces the residual urine volume left in the bladder after urination, when compared to a placebo.

Q: Is it possible for Alfuzosina Teva to cause issues with alertness or confusion?

A: While common side effects are related to dizziness and weakness, official safety documents list confusion among the rare side effects that have been reported with the use of this medicine.

Q: What are the known long-term side effects associated with Alfuzosina Teva?

A: Long-term follow-up studies extending up to a year or more have been conducted. The reported profile of adverse events during these extended periods is generally consistent with the side effects observed over the short term.

Q: Does Alfuzosina Teva affect the results of the PSA blood test for prostate cancer?

A: According to medical literature reviews, Alfuzosin is not associated with a significant impact on the results of the Prostate-Specific Antigen ( PSA) blood test.

Q: Are there any restrictions on driving or operating machinery when first starting Alfuzosina Teva?

A: Official safety warnings describe that driving, operating machinery, or performing hazardous tasks is restricted for a period of 12 hours after taking the initial dose. This caution is necessary, particularly if the user experiences dizziness or fainting.

Q: Has Alfuzosina Teva been studied in patients with both BPH and coronary artery disease?

A: Yes, specific regulatory-reviewed randomized controlled trials have included and studied patients who have concomitant cardiovascular disease. This includes conditions like hypertension or coronary heart disease.

Q: Can Alfuzosina Teva be taken with non-steroidal anti-inflammatory drugs (NSAIDs)?

A: Official documents advise that caution is necessary when Alfuzosin is used with medications that may also impact blood pressure, such as NSAIDs. This concern is particularly noted for patients with pre-existing heart or kidney conditions.

Q: Are there any herbal supplements that are known to interact negatively with Alfuzosina Teva?

A: Regulatory guidance describes the importance of consulting a doctor or pharmacist about the use of any herbal products. This consultation is noted as a step to identify potential negative interactions.

Q: What are the most common reasons why patients stop taking Alfuzosina Teva in clinical trials?

A: The primary reasons for discontinuing the medicine due to side effects in clinical trials are related to its vasodilatory effects. These commonly include dizziness, vertigo, malaise (general discomfort), and hypotension, often occurring during the first week of therapy.

Storage and Disposal of Alfuzosina Teva

Alfuzosina Teva (alfuzosin hydrochloride) must be stored under specific environmental and container constraints to maintain its quality, as defined in regulatory labeling.

---

Storage Requirements

• Temperature and Light: The 10 mg prolonged-release tablets must be stored below 30°C and protected from light. Keep the blister pack in the original outer carton.
• Child Safety: The medication must be kept out of the sight and reach of children.
• Stability: For bottles, the shelf life after first opening is one year, provided this does not exceed the printed expiry date.

---

Disposal Instructions

• Environmental Protection: Do not throw away unused or expired tablets via wastewater or household waste.
• Procedure: Disposal must be carried out in accordance with local requirements. Consult a pharmacist for instructions on proper pharmaceutical waste disposal.